Antiandrogen Treatment with Spironolactone and Linestrenol Decreases Bone Mineral Density in Eumenorrhoeic Women with Androgen Excess
January 1994
in “
Hormone and Metabolic Research
”
TLDR Taking spironolactone and linestrenol for androgen excess can lead to lower bone density in young women.
In a study from 1994, 17 young eumenorrhoeic women with androgen excess, with a median age of 22, were treated with spironolactone and linestrenol for one year, resulting in a significant decrease in bone mineral density (BMD). The mean BMD reduction was 0.032 g/cm² (p<0.001), with 15 of the 17 patients experiencing a decline. A significant correlation was found between the decrease in BMD and reduced androstenedione levels (r=0.5; p=0.037). These results highlight the need to consider the potential impact on BMD when prescribing antiandrogen treatment for functional hyperandrogenemia.
